An interventional study of WM formula liquid drink and Placebo in Obesity, sponsored by TCI Co., Ltd.. Withdrawn at 1 site in Taiwan. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by TCI Co., Ltd. · Not applicable, Interventional, and Prevention
This study aims to evaluate the effects of the combined formula WM Formula, used as a dietary supplement, with a focus on improvements in glycemic and lipid parameters, body composition, and gut microbiota profiles.
This study is a single-center, randomized, double-blind, placebo-controlled human clinical trial designed to evaluate the potential effect of the WM Formula composite supplement on body weight. Eligible participants will be adults aged 18 years or older, screened based on waist circumference or body fat percentage.
Participants will be randomly assigned to one of two groups: one receiving the combined formula WM Formula, and the other receiving a placebo. Each group will take either the WM Formula or placebo, and undergo regular assessments throughout the 4-week study period. Physiological parameters (e.g., height, weight, blood pressure, BMI) and biochemical markers (including liver and kidney function, lipid profile, and blood glucose levels) will be collected at baseline (Week 0), Week 2, and Week 4. In addition, participants will complete appetite assessment questionnaires and other surveys to evaluate changes in appetite and gastrointestinal symptoms.
6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.
Browse Obesity studies →TCI Co., Ltd. is the lead sponsor of 60 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
WM formula liquid drink, 50 g/glass jar
Dietary Supplement: WM formula liquid drink
The placebo contained the same base ingredients as the WM formula but without the active WM formula component.
Dietary Supplement: Placebo
One glass jar (50 g) of the WM formula liquid drink was administered once daily, 1 hour prior to the first meal of the day.
One glass jar (50 g) of the placebo liquid drink was administered once daily, 1 hour prior to the first meal of the day.
Change from baseline in weight at weeks 2 and 4
Assessment of changes in weight at baseline, week 2, and week 4
Time frame: Week 0, 2 and 4
Change from plasma GLP-1 concentration (pmol/L) in baseline at weeks 2 and 4
Time frame: Assessment of changes in GLP-1 concentration at baseline, week 2, and week 4
Change from baseline in blood glucose at weeks 2 and 4
Assessment of blood glucose changes at weeks 0, 2, and 4
Time frame: Week 0, 2 and 4
Change from plasma DPP-4 concentration (ng/mL) in baseline at weeks 2 and 4
Assessment of plasma DPP-4 concentration changes at weeks 0, 2, and 4
Time frame: Week 0, 2 and 4
Change from plasma PAI-1 concentration (ng/mL) in baseline at weeks 2 and 4
Assessment of plasma PAI-1 concentration changes at weeks 0, 2, and 4
Time frame: Week 0, 2 and 4
This study is withdrawn, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
TCI Co., Ltd.